RxDoctor Payments Data

Emmanuel Angeles

Acute Care · Elgin, ILNPI 1629310503

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Johnson & Johnson at 29.3% of the total.

$1,853in general payments, 2019–2025

Across 77 payments — averaging $24.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$543
  • Edwards Lifesciences$209
  • Abbott$192
  • Novo Nordisk$181
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$156
  • Novartis$153
  • plus $419 from 10 others

What the payments were for

  • Food & beverage$1,853100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,853 in reported general payments places this provider in the 85th percentile of 461 acute care providers in Illinois.

See all acute care providers in Illinois

Medicare billing

Part B allowed, 2024
$2,897
Medicare patients
32
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$41,726
JardianceEmpagliflozin57$38,819
XareltoRivaroxaban41$31,002
EntrestoSacubitril/Valsartan22$15,951
BrilintaTicagrelor13$5,383
Bumetanide105$3,169
Metoprolol Succinate227$3,058
Nifedipine ErNifedipine41$1,678
Carvedilol126$1,256
Atorvastatin Calcium130$1,011
Furosemide181$955
Losartan Potassium122$954
Potassium Chloride48$816
Diltiazem 24hr ErDiltiazem Hcl36$775
Rosuvastatin Calcium80$700

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$26$38,81957 claims
Johnson & JohnsonXarelto$543$31,00241 claims
NovartisEntresto$153$15,95122 claims
AstraZenecaBrilinta$20$5,38313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 461 acute care providers in Illinois.

Other acute care in Elgin

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →